CCL2 and colorectal adenocarcinoma: The aim of the present study was to determine whether classic oxicams (piroxicam and meloxicam) and their novel analogues affect the expression and secretion of MCPs (CCL2/MCP-1, CCL7/MCP-3, and CCL8/MCP-2) and MIPs (CCL3/MIP-1α, CCL4/MIP-1β, CCL19/MIP-3β, and CXCL2/MIP-2) in colorectal adenocarcinoma cell lines.